Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Wenzhou Medical UniversityActive in the last 2 years

Guihua Jin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4371-8277; OpenAlex author ID A5103175612. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 9

  1. BCAT1 inhibits glutamine-dependent Akt/mTOR signaling and nucleotide synthesis by initiating BTRC-mediated degradation of SLC3A2 in pancreatic adenocarcinoma. Co-author DOI 10.1186/s40170-026-00436-3↗
  2. Lactate enhances NMNAT1 lactylation to sustain nuclear NAD+ salvage pathway and promote survival of pancreatic adenocarcinoma cells under glucose-deprived cond… Co-author DOI 10.1016/j.canlet.2024.216806↗
  3. Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing Nrf2 activity. Co-author DOI 10.1016/j.phymed.2023.154990↗
  4. Synthetic oleanane triterpenoid derivative CDDO-Me disrupts cellular bioenergetics to suppress pancreatic ductal adenocarcinoma via targeting SLC1A5. Co-author DOI 10.1002/jbt.23192↗
  5. 6-methoxydihydroavicine, the alkaloid extracted from Macleaya cordata (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Caspase-dependent cell death in pancreatic… Co-author DOI 10.1016/j.phymed.2022.154164↗
  6. A synthesized olean-28,13β-lactam targets YTHDF1-GLS1 axis to induce ROS-dependent metabolic crisis and cell death in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-022-02562-6↗
  7. RUNX2 and LAMC2: promising pancreatic cancer biomarkers identified by an integrative data mining of pancreatic adenocarcinoma tissues. Co-author DOI 10.18632/aging.203589↗
  8. Molecular Mechanism of Pancreatic Stellate Cells Activation in Chronic Pancreatitis and Pancreatic Cancer. Co-author DOI 10.7150/jca.38616↗
  9. The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy. First author DOI 10.1155/2014/268479↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Linhua Lan · 6 shared papers, 2021–2026 · strength 1.13
  2. Huimin Huang · 5 shared papers, 2022–2026 · strength 0.93
  3. Fugen Shangguan · 3 shared papers, 2021–2022 · strength 0.48
  4. Shijia Wu · 3 shared papers, 2022 · strength 0.43
  5. Qingqing Ruan · 2 shared papers, 2021–2023 · strength 0.37
  6. Yongheng Bai · 2 shared papers, 2020–2023 · strength 0.32
  7. Percy David Papa Akuetteh · 2 shared papers, 2022 · strength 0.29
  8. Xiaoqun Zheng · 1 shared paper, 2024 · strength 0.19
  9. Hongping Xia · 1 shared paper, 2024 · strength 0.19
  10. Chunmei Wen · 1 shared paper, 2023 · strength 0.18
  11. Jie Deng · 1 shared paper, 2023 · strength 0.18
  12. Guogang Li · 1 shared paper, 2023 · strength 0.18
  13. Hongbao Yang · 1 shared paper, 2022 · strength 0.15
  14. Qiyu Zhang · 1 shared paper, 2022 · strength 0.15
  15. Bicheng Chen · 1 shared paper, 2020 · strength 0.15
  16. Yangyang Guo · 1 shared paper, 2020 · strength 0.15
  17. Nengfang Ma · 1 shared paper, 2022 · strength 0.14
  18. Hongping Xia · 1 shared paper, 2022 · strength 0.14
  19. Hailong Yang · 1 shared paper, 2022 · strength 0.14
  20. Qing Zhu · 1 shared paper, 2014 · strength 0.05
  21. Suxia Han · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.